Charles Schwab Investment Management Inc Celldex Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 544,330 shares of CLDX stock, worth $11.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
544,330
Previous 538,856
1.02%
Holding current value
$11.5 Million
Previous $18.3 Million
24.85%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CLDX
# of Institutions
197Shares Held
69.7MCall Options Held
960KPut Options Held
675K-
Wellington Management Group LLP Boston, MA8.98MShares$189 Million0.04% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.06MShares$107 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$99 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$81.9 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$79.2 Million1.82% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $987M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...